Norma O’Donovan

5.6k citations

116 papers · 4.3k · h-index 36

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
Cancer Research top 2%

Papers in

Oncology 83
- HER2/EGFR in Cancer Research 62
- Peptidase Inhibition and Analysis 16
- Cancer Treatment and Pharmacology 15
- Cancer-related Molecular Pathways 9
Molecular Biology 34

Co-authors: Michael J. Duffy (44 shared papers)John Crown (88 shared papers)Martin Clynes (23 shared papers)Bríd M. Ryan (4 shared papers)Patricia M. McGowan (16 shared papers)B. Corkery (8 shared papers)William M. Gallagher (9 shared papers)Brigid C. Browne (18 shared papers)
Journals: Journal of Clinical Oncology (27 papers)Annals of Oncology (9 papers)Cancer Research (7 papers)Journal of Organometallic Chemistry (5 papers)Investigational New Drugs (5 papers)
Partner nations: Ireland United States United Kingdom

In The Last Decade

Norma O’Donovan

112 papers receiving 4.2k citations

Peers

Replace Monica R. Maiello with:

Monica R. Maiello Italy

Monilola A. Olayioye Germany

Liana Adam United States

Dominic Fan United States

Carlo Leonetti Italy

Moorthy P. Ponnusamy United States

Francesco Caponigro Italy

S. Gail Eckhardt United States

Rita Nahta United States

Antonella De Luca Italy

Norma O’Donovan relative to Monica R. Maiello Italy Monica R. Maiello's profile →

Citations per field

00.5×1.5×2.0×

Monica R. Maiello · 1×

×1.1 2k/2k

ONCOL

×1.1 708/657

CR

×2.0 214/109

IA

×0.9 2k/2k

MB

×0.9 433/461

RNMI

Citations per year

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

'26

Countries citing papers authored by Norma O’Donovan

Since Specialization

Citations

This map shows the geographic impact of Norma O’Donovan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norma O’Donovan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norma O’Donovan more than expected).

Fields of papers citing papers by Norma O’Donovan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norma O’Donovan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norma O’Donovan. The network helps show where Norma O’Donovan may publish in the future.

Co-authors

The 25 scholars most cited alongside Norma O’Donovan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Norma O’Donovan Line = papers co-authored together Norma O’Donovan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 116 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Survivin: A new target for anti-cancer therapy Cancer Treatment Reviews ·Bríd M. Ryan, Norma O’Donovan, Michael J. Duffy	2009	331
2	Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer Annals of Oncology ·B. Corkery, John Crown, Martin Clynes, Norma O’Donovan	2009	282
3	Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib Molecular Cancer Therapeutics ·Neil A. O’Brien, Brigid C. Browne, Lucy Chow, Yuhua Wang, Charles Ginther, Jane Arboleda, Michael J. Duffy, John Crown, Norma O’Donovan, Dennis J. Slamon	2010	249
4	Survivin: A promising tumor biomarker Cancer Letters ·Michael J. Duffy, Norma O’Donovan, Donal J. Brennan, William M. Gallagher, Bríd M. Ryan	2007	213
5	Role of ADAMs in Cancer Formation and Progression Clinical Cancer Research ·Michael J. Duffy, Eadaoin McKiernan, Norma O’Donovan, Patricia M. McGowan	2009	181
6	The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clinical Proteomics ·Michael J. Duffy, Maeve Mullooly, Norma O’Donovan, Sumainizah Sukor, John Crown, Aisling Pierce, Patricia M. McGowan	2011	164
7	Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer Oncotarget ·Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Kasper Pedersen, Neil A. O’Brien, Ioannis Roxanis, Jiliang Li, Esther Bridge, Richard S. Finn, Dennis J. Slamon, Patricia M. McGowan, Michael J. Duffy, Norma O’Donovan, John Crown, Anthony Kong	2013	138
8	Caspase 3 in breast cancer. PubMed ·Norma O’Donovan, John Crown, Helen Stunell, Arnold Hill, Enda McDermott, N. J. O’Higgins, Michael J. Duffy	2003	128
9	Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines Annals of Oncology ·Denis M. Collins, Norma O’Donovan, Patricia M. McGowan, Finbarr O’Sullivan, Michael J. Duffy, John Crown	2011	116
10	Src: a potential target for the treatment of triple-negative breast cancer Annals of Oncology ·Dimitrios Tryfonopoulos, S. Walsh, Denis M. Collins, L. Flanagan, Cecily Quinn, B. Corkery, E. McDermott, Denis Evoy, John P. Pierce, Norma O’Donovan, John Crown, Michael J. Duffy	2011	113
11	BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer Outcome Breast Cancer Research ·Stephen F. Madden, Colin Clarke, Patricia Gaule, Sinéad Aherne, Norma O’Donovan, Martin Clynes, John Crown, William M. Gallagher	2013	110
12	HER-2 Signaling and Inhibition in Breast Cancer Current Cancer Drug Targets ·Brigid C. Browne, Neil A. O’Brien, Michael J. Duffy, John Crown, Norma O’Donovan	2009	94
13	The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells BMC Cancer ·Sharon A. Glynn, DERMOT A. O'SULLIVAN, Alex J. Eustace, Martin Clynes, Norma O’Donovan	2008	88
14	Expression of survivin and its splice variants survivin-2B and survivin-ΔEx3 in breast cancer British Journal of Cancer ·Bríd M. Ryan, Norma O’Donovan, Brigid C. Browne, Caroline O'Shea, John Crown, Arnold Hill, E. McDermott, N. J. O’Higgins, Michael J. Duffy	2004	87
15	Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer? International Journal of Cancer ·Naoise C. Synnott, Alan Murray, Patricia M. McGowan, Maeve Kiely, Patrick A. Kiely, Norma O’Donovan, Darran P. O’Connor, William M. Gallagher, John Crown, Michael J. Duffy	2016	86
16	Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells Annals of Oncology ·Brigid C. Browne, John Crown, Natarajan Venkatesan, Michael J. Duffy, Martin Clynes, Dennis J. Slamon, Norma O’Donovan	2010	84
17	Vitamin D analogues: Potential use in cancer treatment Critical Reviews in Oncology/Hematology ·Michael J. Duffy, Alyson Murray, Naoise C. Synnott, Norma O’Donovan, John Crown	2017	83
18	Use of molecular markers for predicting therapy response in cancer patients Cancer Treatment Reviews ·Michael J. Duffy, Norma O’Donovan, John Crown	2010	78
19	Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines Journal of Translational Medicine ·Alex J. Eustace, John Crown, Martin Clynes, Norma O’Donovan	2008	73
20	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007 Cancer Letters ·Naoise C. Synnott, Matthias R. Bauer, Stephen F. Madden, Alyson Murray, Rut Klinger, Norma O’Donovan, Darran P. O’Connor, William M. Gallagher, John Crown, Alan R. Fersht, Michael J. Duffy	2017	60

About Norma O’Donovan

Norma O’Donovan is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 116 papers that have together received 4.3k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (62 papers), Monoclonal and Polyclonal Antibodies Research (19 papers), Lung Cancer Treatments and Mutations (18 papers), Peptidase Inhibition and Analysis (16 papers), Cancer Treatment and Pharmacology (15 papers), Chronic Lymphocytic Leukemia Research (10 papers), Cancer-related Molecular Pathways (9 papers) and Advanced Breast Cancer Therapies (9 papers). The work is most often cited by research in Oncology (2.0k citations), Cancer Research (708 citations), Immunology and Allergy (214 citations), Molecular Biology (2.0k citations) and Radiology, Nuclear Medicine and Imaging (433 citations). Norma O’Donovan has collaborated with scholars based in Ireland, United States and United Kingdom. Frequent co-authors include Michael J. Duffy, John Crown, Martin Clynes, Bríd M. Ryan, Patricia M. McGowan, B. Corkery, William M. Gallagher, Brigid C. Browne, Neil A. O’Brien and Eadaoin McKiernan. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Journal of Organometallic Chemistry and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Norma O’Donovan

Impact in

Papers in i

In The Last Decade

Norma O’Donovan

Peers

Countries citing papers authored by Norma O’Donovan

Fields of papers citing papers by Norma O’Donovan

All Works

About Norma O’Donovan

Explore authors with similar magnitude of impact

Papers in